Ginkgo Bioworks receives warning from NYSE

In Boston, strain engineering pioneer Ginkgo Bioworks Holdings has received notice from the New York Stock Exchange that the company’s average stock closing price was less than $1 per share over a consecutive 30 trading-day period—setting a countdown for Ginko to boost its price or be delisted.

Under the NYSE rules, Ginkgo now has a six-month period to regain compliance with the minimum price criteria.

Ginkgo said it intends to regain compliance with NYSE’s continued listing standards and is “considering all available options.”